Response to Comments: Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers DL39865

This article is a response document that reviews and addresses public comments on Medicare coverage for skin substitute grafts/cellular and tissue‑based products used to treat diabetic foot ulcers and venous leg ulcers, clarifying the scope of coverage and applicable clinical criteria where relevant rather than making new standalone coverage decisions. All comments from the listed contractors were reviewed and addressed (comments on the same topic may be combined or cross‑referenced), with the responses explaining rationale and any applicable requirements.